An automated network-based tool to search for metabolic vulnerabilities in cancer.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
11 Oct 2024
Historique:
received: 22 06 2022
accepted: 18 09 2024
medline: 12 10 2024
pubmed: 12 10 2024
entrez: 11 10 2024
Statut: epublish

Résumé

The development of computational tools for the systematic prediction of metabolic vulnerabilities of cancer cells constitutes a central question in systems biology. Here, we present gmctool, a freely accessible online tool that allows us to accomplish this task in a simple, efficient and intuitive environment. gmctool exploits the concept of genetic Minimal Cut Sets (gMCSs), a theoretical approach to synthetic lethality based on genome-scale metabolic networks, including a unique database of synthetic lethals computed from Human1, the most recent metabolic reconstruction of human cells. gmctool introduces qualitative and quantitative improvements over our previously developed algorithms to predict, visualize and analyze metabolic vulnerabilities in cancer, demonstrating a superior performance than competing algorithms. A detailed illustration of gmctool is presented for multiple myeloma (MM), an incurable hematological malignancy. We provide in vitro experimental evidence for the essentiality of CTPS1 (CTPS synthase) and UAP1 (UDP-N-Acetylglucosamine Pyrophosphorylase 1) in specific MM patient subgroups.

Identifiants

pubmed: 39394196
doi: 10.1038/s41467-024-52725-4
pii: 10.1038/s41467-024-52725-4
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

8685

Subventions

Organisme : Ministerio de Economía y Competitividad (Ministry of Economy and Competitiveness)
ID : PID2019-110344RB-I00, PID2022-143298OB-I00

Informations de copyright

© 2024. The Author(s).

Références

Robinson, J. L. et al. An atlas of human metabolism. Sci. Signal. 13, 1–12 (2020).
doi: 10.1126/scisignal.aaz1482
Cook, D. J. & Nielsen, J. Genome-scale metabolic models applied to human health and disease. Wiley Interdiscip. Rev. Syst. Biol. Med. 9, e1393 (2017).
doi: 10.1002/wsbm.1393
Lewis, N. E. & Abdel-Haleem, A. M. The evolution of genome-scale models of cancer metabolism. Front. Physiol. 0, 237 (2013).
Ghaffari, P., Mardinoglu, A. & Nielsen, J. Cancer metabolism: a modeling perspective. Front. Physiol. 0, 382 (2015).
Lewis, N. E., Nagarajan, H. & Palsson, B. O. Constraining the metabolic genotype–phenotype relationship using a phylogeny of in silico methods. Nat. Rev. Microbiol. 10, 291–305 (2012).
doi: 10.1038/nrmicro2737 pubmed: 22367118 pmcid: 3536058
Tobalina, L., Pey, J., Rezola, A. & Planes, F. J. Assessment of FBA based gene essentiality analysis in cancer with a fast context-specific network reconstruction method. PLoS ONE 11, e0154583 (2016).
doi: 10.1371/journal.pone.0154583 pubmed: 27145226 pmcid: 4856428
Folger, O. et al. Predicting selective drug targets in cancer through metabolic networks. Mol. Syst. Biol. 7, 501 (2011).
doi: 10.1038/msb.2011.35 pubmed: 21694718 pmcid: 3159974
Apaolaza, I. et al. An in-silico approach to predict and exploit synthetic lethality in cancer metabolism. Nat. Commun. 8, 1–9 (2017).
doi: 10.1038/s41467-017-00555-y
Apaolaza, I., Valcarcel, L. V. & Planes, F. J. GMCS: fast computation of genetic minimal cut sets in large networks. Bioinformatics 35, 535–537 (2019).
doi: 10.1093/bioinformatics/bty656 pubmed: 30052768
Thiele, I. et al. A community-driven global reconstruction of human metabolism. Nat. Biotechnol. 31, 419–425 (2013).
doi: 10.1038/nbt.2488 pubmed: 23455439
Meyers, R. M. et al. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat. Genet. 49, 1779–1784 (2017).
doi: 10.1038/ng.3984 pubmed: 29083409 pmcid: 5709193
Ghandi, M. et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569, 503–508 (2019).
doi: 10.1038/s41586-019-1186-3 pubmed: 31068700 pmcid: 6697103
Agren, R. et al. Identification of anticancer drugs for hepatocellular carcinoma through personalized genome-scale metabolic modeling. Mol. Syst. Biol. 10, 721 (2014).
doi: 10.1002/msb.145122 pubmed: 24646661 pmcid: 4017677
Costanzo, M. et al. A global genetic interaction network maps a wiring diagram of cellular function. Science 353, aaf1420 (2016).
doi: 10.1126/science.aaf1420 pubmed: 27708008 pmcid: 5661885
McCall, M. N. et al. The Gene Expression Barcode 3.0: improved data processing and mining tools. Nucleic Acids Res. 42, D938–D943 (2014).
doi: 10.1093/nar/gkt1204 pubmed: 24271388
Richelle, A., Joshi, C. & Lewis, N. E. Assessing key decisions for transcriptomic data integration in biochemical networks. PLoS Comput. Biol. 15, e1007185 (2019).
doi: 10.1371/journal.pcbi.1007185 pubmed: 31323017 pmcid: 6668847
Gonatopoulos-Pournatzis, T. et al. Genetic interaction mapping and exon-resolution functional genomics with a hybrid Cas9-Cas12a platform. Nat. Biotechnol. 38, 638–648 (2020).
doi: 10.1038/s41587-020-0437-z pubmed: 32249828
Thompson, N. A. et al. Combinatorial CRISPR screen identifies fitness effects of gene paralogues. Nat. Commun. 12, 1302 (2021).
doi: 10.1038/s41467-021-21478-9 pubmed: 33637726 pmcid: 7910459
De Kegel, B., Quinn, N., Thompson, N. A., Adams, D. J. & Ryan, C. J. Comprehensive prediction of robust synthetic lethality between paralog pairs in cancer cell lines. Cell Syst. 12, 1144–1159.e6 (2021).
doi: 10.1016/j.cels.2021.08.006 pubmed: 34529928
Muller, F. L. et al. Passenger deletions generate therapeutic vulnerabilities in cancer. Nature 488, 337–342 (2012).
doi: 10.1038/nature11331 pubmed: 22895339 pmcid: 3712624
Agirre, X. et al. Long non-coding RNAs discriminate the stages and gene regulatory states of human humoral immune response. Nat. Commun. 10, 821 (2019).
doi: 10.1038/s41467-019-08679-z pubmed: 30778059 pmcid: 6379396
Ordoñez, R. et al. Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma. Genome Res. 30, 1217–1227 (2020).
doi: 10.1101/gr.265520.120 pubmed: 32820006 pmcid: 7545147
Carrasco-Leon, A. et al. Characterization of complete lncRNAs transcriptome reveals the functional and clinical impact of lncRNAs in multiple myeloma. Leukemia 35, 1438–1450 (2021).
doi: 10.1038/s41375-021-01147-y pubmed: 33597729 pmcid: 8102198
Martin, E. et al. CTP synthase 1 deficiency in humans reveals its central role in lymphocyte proliferation. Nature 510, 288–292 (2014).
doi: 10.1038/nature13386 pubmed: 24870241 pmcid: 6485470
Lynch, E. M. et al. Structural basis for isoform-specific inhibition of human CTPS1. Proc. Natl Acad. Sci. USA 118, e2107968118 (2021).
doi: 10.1073/pnas.2107968118 pubmed: 34583994 pmcid: 8501788
Chiron, D. et al. STP938, a selective CTPS1 inhibitor, shows single agent activity and synergy with BCL2 inhibition in preclinical models of mantle cell lymphoma. Blood 140, 6014–6015 (2022).
doi: 10.1182/blood-2022-159449
Rao, Y. et al. Targeting CTP synthetase 1 to restore interferon induction and impede nucleotide synthesis in SARS-CoV-2 infection. Preprint at bioRxiv https://doi.org/10.1101/2021.02.05.429959 (2021).
Wu, J. L. et al. O-GlcNAcylation is required for B cell homeostasis and antibody responses. Nat. Commun. 8, 1–10 (2017).
doi: 10.1038/s41467-017-01677-z
Chesi, M. et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat. Genet. 16, 260–264 (1997).
doi: 10.1038/ng0797-260 pubmed: 9207791 pmcid: 3901950
Colaprico, A. et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 44, e71–e71 (2016).
doi: 10.1093/nar/gkv1507 pubmed: 26704973
Piao, C. et al. Inhibition of stearoyl CoA desaturase-1 activity suppresses tumour progression and improves prognosis in human bladder cancer. J. Cell. Mol. Med. 23, 2064–2076 (2019).
doi: 10.1111/jcmm.14114 pubmed: 30592142
Chajès, V., Cambot, M., Moreau, K., Lenoir, G. M. & Joulin, V. Acetyl-CoA carboxylase α is essential to breast cancer cell survival. Cancer Res. 66, 5287–5294 (2006).
doi: 10.1158/0008-5472.CAN-05-1489 pubmed: 16707454
Li, S. et al. Acetyl-CoA-carboxylase 1-mediated de novo fatty acid synthesis sustains Lgr5+ intestinal stem cell function. Nat. Commun. 13, 3998 (2022).
doi: 10.1038/s41467-022-31725-2 pubmed: 35810180 pmcid: 9271096
Agren, R. et al. Reconstruction of genome-scale active metabolic networks for 69 human cell types and 16 cancer types using INIT. PLoS Comput. Biol. 8, e1002518 (2012).
doi: 10.1371/journal.pcbi.1002518 pubmed: 22615553 pmcid: 3355067
Dikicioglu, D., Kırdar, B. & Oliver, S. G. Biomass composition: the “elephant in the room” of metabolic modelling. Metabolomics 11, 1690–1701 (2015).
doi: 10.1007/s11306-015-0819-2 pubmed: 26491422 pmcid: 4605984
Lachance, J. C. et al. BOFdat: generating biomass objective functions for genome-scale metabolic models from experimental data. PLoS Comput. Biol. 15, e1006971 (2019).
doi: 10.1371/journal.pcbi.1006971 pubmed: 31009451 pmcid: 6497307
Moscardó García, M., Pacheco, M., Bintener, T., Presta, L. & Sauter, T. Importance of the biomass formulation for cancer metabolic modeling and drug prediction. iScience 24, 103110 (2021).
doi: 10.1016/j.isci.2021.103110 pubmed: 34622163 pmcid: 8482493
Hernández Patiño, C. E., Jaime-Muñoz, G. & Resendis-Antonio, O. Systems biology of cancer: moving toward the integrative study of the metabolic alterations in cancer cells. Front. Physiol. 3, 481 (2013).
doi: 10.3389/fphys.2012.00481 pubmed: 23316163 pmcid: 3539652
Zielinski, D. C. et al. Systems biology analysis of drivers underlying hallmarks of cancer cell metabolism. Sci. Rep. 7, 1–14 (2017).
doi: 10.1038/srep41241
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
doi: 10.1016/j.cell.2011.02.013 pubmed: 21376230
Pey, J. et al. In-silico gene essentiality analysis of polyamine biosynthesis reveals APRT as a potential target in cancer. Sci. Rep. 7, 1–10 (2017).
doi: 10.1038/s41598-017-14067-8
Duarte, N. C. et al. Global reconstruction of the human metabolic network based on genomic and bibliomic data. Proc. Natl Acad. Sci. USA 104, 1777–1782 (2007).
doi: 10.1073/pnas.0610772104 pubmed: 17267599 pmcid: 1794290
Swainston, N. et al. Recon 2.2: from reconstruction to model of human metabolism. Metabolomics 12, 1–7 (2016).
doi: 10.1007/s11306-016-1051-4
Orth, J. D., Thiele, I. & Palsson, B. Ø. What is flux balance analysis? Nat. Biotechnol. 28, 245–248 (2010).
doi: 10.1038/nbt.1614 pubmed: 20212490 pmcid: 3108565
Heirendt, L. et al. Creation and analysis of biochemical constraint-based models using the COBRA Toolbox v.3.0. Nat. Protoc. 14, 639–702 (2019).
doi: 10.1038/s41596-018-0098-2 pubmed: 30787451 pmcid: 6635304
Wang, H. et al. RAVEN 2.0: a versatile toolbox for metabolic network reconstruction and a case study on Streptomyces coelicolor. PLoS Comput. Biol. 14, 1–17 (2018).
doi: 10.1371/journal.pcbi.1006541
R Core Team. R: a language and environment for statistical computing (R Foundation for Statistical Computing, Vienna, Austria, 2021). https://www.R-project.org/ .
Chang, W. et al. shiny: web application framework for R (2021). https://shiny.rstudio.com/ , https://shiny.posit.co
Valcarcel, L. V. et al. Scripts and code for ‘gmctool: automated network-based tool to search for metabolic vulnerabilities in cancer’. Zenodo https://doi.org/10.5281/zenodo.13285245 (2024).

Auteurs

Luis V Valcárcel (LV)

University of Navarra, Tecnun School of Engineering, Manuel de Lardizábal 13, 20018, San Sebastián, Spain.
Hemato-Oncology Program, Center for Applied Medical Research (CIMA), Universidad de Navarra, IDISNA, CCUN, Avenida Pío XII 55, 31008, Pamplona, Spain.

Edurne San José-Enériz (E)

Hemato-Oncology Program, Center for Applied Medical Research (CIMA), Universidad de Navarra, IDISNA, CCUN, Avenida Pío XII 55, 31008, Pamplona, Spain.
CIBERONC Centro de Investigación Biomédica en Red de Cáncer, 28029, Madrid, Spain.

Raquel Ordoñez (R)

Hemato-Oncology Program, Center for Applied Medical Research (CIMA), Universidad de Navarra, IDISNA, CCUN, Avenida Pío XII 55, 31008, Pamplona, Spain.
CIBERONC Centro de Investigación Biomédica en Red de Cáncer, 28029, Madrid, Spain.

Iñigo Apaolaza (I)

University of Navarra, Tecnun School of Engineering, Manuel de Lardizábal 13, 20018, San Sebastián, Spain.

Danel Olaverri-Mendizabal (D)

University of Navarra, Tecnun School of Engineering, Manuel de Lardizábal 13, 20018, San Sebastián, Spain.

Naroa Barrena (N)

University of Navarra, Tecnun School of Engineering, Manuel de Lardizábal 13, 20018, San Sebastián, Spain.

Ana Valcárcel (A)

Hemato-Oncology Program, Center for Applied Medical Research (CIMA), Universidad de Navarra, IDISNA, CCUN, Avenida Pío XII 55, 31008, Pamplona, Spain.

Leire Garate (L)

Hemato-Oncology Program, Center for Applied Medical Research (CIMA), Universidad de Navarra, IDISNA, CCUN, Avenida Pío XII 55, 31008, Pamplona, Spain.
CIBERONC Centro de Investigación Biomédica en Red de Cáncer, 28029, Madrid, Spain.

Jesús San Miguel (J)

Hemato-Oncology Program, Center for Applied Medical Research (CIMA), Universidad de Navarra, IDISNA, CCUN, Avenida Pío XII 55, 31008, Pamplona, Spain.
CIBERONC Centro de Investigación Biomédica en Red de Cáncer, 28029, Madrid, Spain.
Departmento de Hematología, Clínica Universidad de Navarra and CCUN, Universidad de Navarra, Avenida Pío XII 36, 31008, Pamplona, Spain.

Antonio Pineda-Lucena (A)

Hemato-Oncology Program, Center for Applied Medical Research (CIMA), Universidad de Navarra, IDISNA, CCUN, Avenida Pío XII 55, 31008, Pamplona, Spain.
CIBERONC Centro de Investigación Biomédica en Red de Cáncer, 28029, Madrid, Spain.

Xabier Agirre (X)

Hemato-Oncology Program, Center for Applied Medical Research (CIMA), Universidad de Navarra, IDISNA, CCUN, Avenida Pío XII 55, 31008, Pamplona, Spain.
CIBERONC Centro de Investigación Biomédica en Red de Cáncer, 28029, Madrid, Spain.

Felipe Prósper (F)

Hemato-Oncology Program, Center for Applied Medical Research (CIMA), Universidad de Navarra, IDISNA, CCUN, Avenida Pío XII 55, 31008, Pamplona, Spain. fprosper@unav.es.
CIBERONC Centro de Investigación Biomédica en Red de Cáncer, 28029, Madrid, Spain. fprosper@unav.es.
Departmento de Hematología, Clínica Universidad de Navarra and CCUN, Universidad de Navarra, Avenida Pío XII 36, 31008, Pamplona, Spain. fprosper@unav.es.

Francisco J Planes (FJ)

University of Navarra, Tecnun School of Engineering, Manuel de Lardizábal 13, 20018, San Sebastián, Spain. fplanes@tecnun.es.
Biomedical Engineering Center, University of Navarra, 31008, Pamplona, Navarra, Spain. fplanes@tecnun.es.
University of Navarra, Instituto de Ciencia de los Datos e Inteligencia Artificial (DATAI), Campus Universitario, 31008, Pamplona, Spain. fplanes@tecnun.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH